Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR-positive/HER2-negative BC patients: results from the multicenter PALMARES-2 study
Titel:
Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR-positive/HER2-negative BC patients: results from the multicenter PALMARES-2 study
Auteur:
Provenzano, L. Dieci, M.V. Curigliano, G. Giuliano, M. Botticelli, A. Lambertini, M. Rizzo, G. Pedersini, R. Sirico, M. La Verde, N. Gennari, A. Zambelli, A. Toss, A. Piras, M. Giordano, M. Tagliaferri, B. Generali, D. Sartori, D. Miliziano, D. Menichetti, A. Ligorio, F. Zurlo, C. Griguolo, G. Berton Giachetti, P.P. Faso, V. Corti, C. Chiappe, E. Scagnoli, S. Pisegna, S. Capasso, C. De Angelis, C. Arpino, G. Criscitiello, C. Guarneri, V. Pruneri, G. Mariani, L. Vernieri, C.